|
US7902338B2
(en)
*
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
RS53263B
(sr)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
Optimizovana antitela usmerena na cd19
|
|
US8323653B2
(en)
|
2006-09-08 |
2012-12-04 |
Medimmune, Llc |
Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
CL2007003622A1
(es)
*
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
|
AU2014201846B2
(en)
*
|
2007-01-30 |
2016-07-07 |
Epivax, Inc. |
Regulatory t cell epitopes, compositions and uses thereof
|
|
EP2423220B1
(en)
|
2007-01-30 |
2015-04-29 |
Epivax, Inc. |
Regulatory t cell epitopes, compositions and uses thereof
|
|
WO2008109493A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof
|
|
US20110014117A1
(en)
*
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
EP2185188B1
(en)
|
2007-08-22 |
2014-08-06 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
|
|
CN101903403B
(zh)
|
2007-10-19 |
2016-03-16 |
西雅图基因公司 |
Cd19结合剂及其应用
|
|
CA2753158A1
(en)
*
|
2009-02-23 |
2010-08-26 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to cd19 and their uses
|
|
US8394922B2
(en)
|
2009-08-03 |
2013-03-12 |
Medarex, Inc. |
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
|
|
WO2011123819A2
(en)
*
|
2010-04-01 |
2011-10-06 |
Kalobios Pharmaceuticals, Inc. |
Epha3 antibodies for the treatment of multiple myeloma
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
BR112013007293A2
(pt)
|
2010-10-05 |
2016-06-14 |
Hoffmann La Roche |
anticorpos contra a tweak de seres humanos e suas utilizações
|
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
|
SG10201606785UA
(en)
|
2011-08-16 |
2016-10-28 |
Morphosys Ag |
Combination therapy with an anti - cd19 antibody and a nitrogen mustard
|
|
CA2841738C
(en)
|
2011-08-16 |
2022-12-06 |
Morphosys Ag |
Combination therapy with an anti-cd19 antibody and a purine analog
|
|
PL2814829T3
(pl)
|
2012-02-13 |
2017-06-30 |
Bristol-Myers Squibb Company |
Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania
|
|
RU2693078C2
(ru)
*
|
2012-12-03 |
2019-07-01 |
Новиммун С.А. |
Анти-cd47 антитела и способы их применения
|
|
DK2956173T3
(en)
|
2013-02-14 |
2017-07-17 |
Bristol Myers Squibb Co |
TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
|
|
JP6474404B2
(ja)
|
2013-08-14 |
2019-02-27 |
ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ |
ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
US10077287B2
(en)
|
2014-11-10 |
2018-09-18 |
Bristol-Myers Squibb Company |
Tubulysin analogs and methods of making and use
|
|
ES2826566T3
(es)
|
2014-11-21 |
2021-05-18 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas
|
|
CN107231804B
(zh)
|
2015-01-14 |
2019-11-26 |
百时美施贵宝公司 |
亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
|
|
JP6916741B2
(ja)
|
2015-05-26 |
2021-08-11 |
モルフォシス・アーゲー |
抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
|
|
EP3304079B1
(en)
|
2015-06-03 |
2020-06-03 |
Bristol-Myers Squibb Company |
Anti-gitr antibodies for cancer diagnostics
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
AU2016311136B2
(en)
|
2015-08-21 |
2022-02-17 |
Incyte Corporation |
Combinations and uses thereof
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
AR106188A1
(es)
*
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3356405B1
(en)
|
2015-10-02 |
2026-07-08 |
F. Hoffmann-La Roche AG |
Anti-human cd19 antibodies with high affinity
|
|
EP3356407B1
(en)
*
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
SG11201803054UA
(en)
*
|
2015-10-13 |
2018-05-30 |
Eureka Therapeutics Inc |
Antibody agents specific for human cd19 and uses thereof
|
|
MX2018004721A
(es)
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
|
EP3394096A1
(en)
|
2015-12-21 |
2018-10-31 |
Bristol-Myers Squibb Company |
Variant antibodies for site-specific conjugation
|
|
ES2954153T3
(es)
|
2015-12-22 |
2023-11-20 |
Regeneron Pharma |
Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
|
|
JP2019518013A
(ja)
|
2016-05-10 |
2019-06-27 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
安定性が向上したツブリシン類似体の抗体薬物結合体
|
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
ES2981046T3
(es)
|
2016-05-30 |
2024-10-07 |
Incyte Corp |
Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
|
|
SMT202100317T1
(it)
|
2016-06-27 |
2021-07-12 |
Morphosys Ag |
Formulazioni di anticorpi anti-cd19
|
|
US10398783B2
(en)
|
2016-10-20 |
2019-09-03 |
Bristol-Myers Squibb Company |
Antiproliferative compounds and conjugates made therefrom
|
|
WO2018078123A1
(en)
|
2016-10-28 |
2018-05-03 |
Morphosys Ag |
Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
CN106978400A
(zh)
*
|
2016-12-13 |
2017-07-25 |
无锡傲锐东源生物科技有限公司 |
抗pd‑l1蛋白单克隆抗体及其用途
|
|
CN116120454A
(zh)
*
|
2017-01-05 |
2023-05-16 |
上海煦顼技术有限公司 |
人源化抗cd19抗体及其与嵌合抗原受体的用途
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
WO2018200582A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
|
WO2018213297A1
(en)
|
2017-05-16 |
2018-11-22 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
|
MX2019013132A
(es)
|
2017-05-25 |
2020-01-27 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas.
|
|
HUE063119T2
(hu)
|
2017-05-31 |
2024-01-28 |
Morphosys Ag |
Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez
|
|
SG11201912865VA
(en)
*
|
2017-06-25 |
2020-01-30 |
Systimmune Inc |
Multi-specific antibodies and methods of making and using thereof
|
|
US11787863B2
(en)
*
|
2017-06-25 |
2023-10-17 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
CN109535257B
(zh)
|
2017-09-22 |
2021-05-28 |
同润生物医药(上海)有限公司 |
新型双特异性cd3/cd19多肽复合物
|
|
JP7089806B2
(ja)
|
2017-12-06 |
2022-06-23 |
アブクロン・インコーポレイテッド |
悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
|
|
WO2019209811A1
(en)
|
2018-04-24 |
2019-10-31 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (tlr7) agonists
|
|
JP7458997B2
(ja)
|
2018-05-29 |
2024-04-01 |
ブリストル－マイヤーズ スクイブ カンパニー |
プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
KR20200030337A
(ko)
*
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
JP2022513653A
(ja)
|
2018-11-28 |
2022-02-09 |
ブリストル－マイヤーズ スクイブ カンパニー |
修飾された重鎖定常領域を含む抗体
|
|
DK3886914T3
(da)
|
2018-11-30 |
2023-07-03 |
Bristol Myers Squibb Co |
Antistof omfattende en glutaminholdig letkæde-c-terminal forlængelse, konjugater deraf og fremgangsmåder samt anvendelser
|
|
WO2020123425A2
(en)
|
2018-12-12 |
2020-06-18 |
Bristol-Myers Squibb Company |
Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
|
|
KR20250116790A
(ko)
|
2018-12-12 |
2025-08-01 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
WO2020141145A1
(en)
|
2018-12-30 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
Anti-rabbit cd19 antibodies and methods of use
|
|
CN110396128B
(zh)
*
|
2019-03-21 |
2022-09-06 |
南京东极医药科技有限公司 |
抗cd19纳米抗体的制备
|
|
CN114072424A
(zh)
|
2019-05-03 |
2022-02-18 |
莫佛塞斯公司 |
具有有限数量的nk细胞的患者中的抗cd19疗法
|
|
AU2020277525B2
(en)
*
|
2019-05-20 |
2026-06-11 |
Nanjing IASO Biotechnology Co., Ltd. |
Fully human antibody targeting CD19 and application thereof
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
US20240377413A1
(en)
|
2019-09-16 |
2024-11-14 |
Bristol-Myers Squibb Company |
Dual capture method for analysis of antibody-drug conjugates
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
WO2021084062A1
(en)
|
2019-10-31 |
2021-05-06 |
Morphosys Ag |
Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
|
|
LT4051710T
(lt)
|
2019-10-31 |
2026-03-10 |
Incyte Corporation |
Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
|
|
CN115916818A
(zh)
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗cd19抗体和多特异性结合蛋白
|
|
WO2021165488A1
(en)
|
2020-02-21 |
2021-08-26 |
Genmab B.V. |
Methods for the quantification of glycoproteins
|
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
CR20220637A
(es)
|
2020-06-19 |
2023-01-31 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
|
EP4168449A1
(en)
|
2020-06-22 |
2023-04-26 |
MorphoSys AG |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
|
|
TWI914420B
(zh)
|
2020-10-06 |
2026-02-11 |
美商山可爾股份有限公司 |
用於治療包括全身性紅斑性狼瘡(sle)的自體免疫疾病之生物標記、方法及組合物
|
|
AU2021391623A1
(en)
|
2020-12-04 |
2023-06-29 |
Incyte Corporation |
Anti-cd19 combination therapy
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
IL318787A
(en)
|
2022-08-17 |
2025-04-01 |
Incyte Corp |
Treatment including ANTI-CD19 antibodies and EZH2 modulators
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記５５有限公司 |
Ｃｄ１９／ｃｄ３８多特異性抗體
|
|
WO2024258866A1
(en)
|
2023-06-12 |
2024-12-19 |
Interius Biotherapeutics, Inc. |
Compositions and methods for the treatment of immunological disorders
|
|
JP2026520754A
(ja)
|
2023-06-14 |
2026-06-24 |
インテリウス・バイオセラピューティクス・インコーポレイテッド |
遺伝子操作されたキメラ受容体タンパク質を含む偽型ウイルス粒子
|
|
WO2025076419A1
(en)
*
|
2023-10-04 |
2025-04-10 |
Kyverna Therapeutics, Inc. |
Methods for treating systemic sclerosis using anti-cd19 car-t cell therapies
|
|
TW202545992A
(zh)
|
2024-01-23 |
2025-12-01 |
中國大陸商上海藥明生物技術有限公司 |
靶向ｃｄ３、ｃｄ１９及ｃｄ２０之多特異性抗體及其用途
|
|
WO2025188694A1
(en)
|
2024-03-05 |
2025-09-12 |
Bristol-Myers Squibb Company |
Tricyclic tlr7 agonists and uses thereof
|
|
US20250282776A1
(en)
|
2024-03-05 |
2025-09-11 |
Bristol-Myers Squibb Company |
Bicyclic TLR7 Agonists and Uses Thereof
|
|
WO2026084978A1
(en)
*
|
2024-10-14 |
2026-04-23 |
Climb Bio Operating Inc. |
Processes and compositions for production of anti-cd19 antibodies
|
|
WO2026158539A1
(zh)
*
|
2025-01-24 |
2026-07-30 |
信达生物制药(苏州)有限公司 |
靶向cd19，bcma和cd3的三特异性抗体及其用途
|